43.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
WCM Investment Management LLC Has $5.73 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by abrdn plc - MarketBeat
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study - MSN
Ultragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements - TipRanks
Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $92.43 - MarketBeat
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update - GlobeNewswire
Rare Disease Leader Ultragenyx to Reveal Full Year Performance: Key Earnings Date Announced - StockTitan
UX111 offers cognitive, motor skill gains in Sanfilippo syndrome type A - Sanfilippo News
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Adicet's T-Cell Therapy ADI-100 Fast Tracked by FDA for Refractory Systemic Lupus Erythematosus - CGTLive™
Ultragenyx announces new data on UX111 AV gene therapy - Yahoo Finance
Ultragenyx updates on UX111 AAV gene therapy - The Pharma Letter
Ultragenyx links cognitive improvement to biomarker in latest Sanfilippo gene therapy readout - FirstWord Pharma
Ultragenyx Announces New Data Demonstrating that Treatment - GlobeNewswire
Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2 - Marketscreener.com
Ultragenyx reports positive data on gene therapy for rare disease - MSN
Ultragenyx reports positive data on gene therapy for rare disease By Investing.com - Investing.com South Africa
Breakthrough: Ultragenyx's Gene Therapy Reverses Cognitive Decline in Fatal Childhood Disease - StockTitan
KBC Group NV Buys 58,442 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Ultragenyx Pharmaceutical: Advancing On Multiple Fronts (NASDAQ:RARE) - Seeking Alpha
Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market - Barchart
Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive™
Learn to Evaluate (RARE) using the Charts - Stock Traders Daily
Ultragenyx Pharmaceutical (NASDAQ:RARE) adds US$374m to market cap in the past 7 days, though investors from three years ago are still down 37% - Simply Wall St
What is Wedbush’s Estimate for RARE FY2024 Earnings? - Defense World
Wedbush Has Positive Outlook for RARE FY2027 Earnings - Defense World
Wedbush Equities Analysts Boost Earnings Estimates for RARE - MarketBeat
Ultragenyx's SWOT analysis: rare disease stock poised for growth - Investing.com India
Cantor Fitzgerald Forecasts RARE FY2025 Earnings - Defense World
FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs - Defense World
Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR
Ultragenyx's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Australia
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views - Benzinga
Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Leerink Partnrs Has Positive Outlook of RARE FY2024 Earnings - MarketBeat
Cantor Fitzgerald Predicts RARE FY2025 Earnings - MarketBeat
Assenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):